Additionally, FAHFAs can inhibit the NF-κB signaling pathway, reducing the secretion of pro-inflammatory cytokines and thus altering the tumor immune microenvironment (Li et al., 2024b; Deng et al., 2016). This evidence concerns the gene NFKB1 and neoplasm.